194423-06-8

• 常用中文名：N-[4-[(3-溴苯基)氨基]-6-喹唑啉基]-2-丁炔酰胺
• 常用英文名：CL-387,785
• CAS号：194423-06-8
• 分子式：C₁₈H₁₃BrN₄O
• 分子量：381.226
• 相关类别： 生物化工 抑制剂 蛋白酪氨酸激酶
• 发布时间：2018-12-28 19:44:14
• 更新时间：2026-07-02 18:01:17

名称

• 中文名: N-[4-[(3-溴苯基)氨基]-6-喹唑啉基]-2-丁炔酰胺
• 英文名: N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
• 中文别名: N-(4-((3-溴苯基)氨基)喹唑啉-6-基)丁-2-炔酰胺
• 英文别名: N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-butynamide; WAY-EKI; CL-387785, >=; 2-ButynaMide, N-[4-[(3-broMophenyl)amino]-6-quinazolinyl]- //BP; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide; CL-387785, 10 mM in DMSO; EKI-785; EKI-785 CL-38875; CL-387785 (EKI-785) ，S7557; 4-anilinoquinazoline deriv. 1; EKI-785; WAY-EKI 785; CL387785; CL 387785; EKI785; WAY-EKI785; EKI 785;CL-387; CL-387785 (EKI-785); N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; 387785; CL-38875; CL-387; CL-387785; N-[4-[(3-broMophenyl)amino]-6-quinazolinyl]-2-ButynaMide CL-387785; UNII-B4W27J1Z8B; 2-ButynaMide, N-[4-[(3-broMophenyl)amino]-6-quinazolinyl]; CL-387785,ErbB-1,HER1,CL387785,EGFR,EKI785,inhibit,Inhibitor,CL 387785,EKI 785,idermal owth factor rector; N-(4-(3-bromophenylamino)quinazolin-6-yl)but-2-ynamide

物化性质

• 密度: 1.6±0.1 g/cm3
• 熔点: 276 °C
• 分子式: C₁₈H₁₃BrN₄O
• 分子量: 381.226
• 精确质量: 380.027252
• PSA: 70.40000
• LogP: 4.68
• 外观性状: 固体;White to Orange to Green powder to crystal
• 折射率: 1.755
• 储存条件: <0°C;避免加热

生物活性

• 相关类别:
  研究领域 >> 癌症
• 靶点:

  EGFR:370 pM (IC50)

• 参考文献:

  [1]. Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25.

  [2]. Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40.

  [3]. Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.

  [4]. Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101.

合成路线

590-93-2 169205-78-1 ~4% 194423-06-8

文献：Klutchko, Sylvester R.; Zhou, Hairong; Winters, R. Thomas; Tran, Tuan P.; Bridges, Alexander J.; Althaus, Irene W.; Amato, Danielle M.; Elliott, William L.; Ellis, Paul A.; Meade, Mary Ann; Roberts, Billy J.; Fry, David W.; Gonzales, Andrea J.; Harvey, Patricia J.; Nelson, James M.; Sherwood, Veronica; Han, Hyo-Kyung; Pace, Gerry; Smaill, Jeff B.; Denny, William A.; Showalter, H. D. Hollis Journal of Medicinal Chemistry, 2006 , vol. 49, # 4 p. 1475 - 1485

208533-38-4 591-19-5 ~% 194423-06-8

文献：Wyeth Holdings Corporation Patent: EP1000039 B1, 2004 ; Location in patent: Page 34 ;

109-02-4 590-93-2 169205-78-1 543-27-1 ~% 详细

文献：American Cyanamid Company Patent: US6323209 B1, 2001 ;

194423-18-2 591-19-5 ~% 194423-06-8

文献：Wyeth Holdings Corporation Patent: EP1000039 B1, 2004 ; Location in patent: Page 35 ;

17420-30-3 ~% 194423-06-8

文献：Tsou; Mamuya; Johnson; Reich; Gruber; Ye; Nilakantan; Shen; Discafani; DeBlanc; Davis; Koehn; Greenberger; Wang; Wissner Journal of Medicinal Chemistry, 2001 , vol. 44, # 17 p. 2719 - 2734

169205-77-0 ~% 194423-06-8

文献：Tsou; Mamuya; Johnson; Reich; Gruber; Ye; Nilakantan; Shen; Discafani; DeBlanc; Davis; Koehn; Greenberger; Wang; Wissner Journal of Medicinal Chemistry, 2001 , vol. 44, # 17 p. 2719 - 2734